Loxo Oncology, Inc. (NASDAQ:LOXO) Director Keith T. Flaherty sold 7,250 shares of the company’s stock in a transaction on Monday, November 20th. The shares were sold at an average price of $75.99, for a total value of $550,927.50. Following the transaction, the director now directly owns 12,493 shares in the company, valued at approximately $949,343.07. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Shares of Loxo Oncology, Inc. (LOXO) opened at $75.64 on Friday. Loxo Oncology, Inc. has a fifty-two week low of $25.25 and a fifty-two week high of $95.92.

WARNING: This report was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/11/24/keith-t-flaherty-sells-7250-shares-of-loxo-oncology-inc-loxo-stock.html.

A number of analysts recently issued reports on the company. Stifel Nicolaus reiterated a “buy” rating and set a $94.00 price objective (up from $71.00) on shares of Loxo Oncology in a research note on Thursday, August 10th. BidaskClub upgraded Loxo Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. Zacks Investment Research lowered Loxo Oncology from a “buy” rating to a “hold” rating in a research note on Saturday, August 12th. Ifs Securities restated an “outperform” rating on shares of Loxo Oncology in a research note on Tuesday, August 8th. Finally, Citigroup Inc. decreased their target price on Loxo Oncology from $112.00 to $108.00 and set a “buy” rating on the stock in a research note on Thursday, November 16th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Loxo Oncology presently has an average rating of “Buy” and an average price target of $90.57.

Hedge funds have recently modified their holdings of the stock. Quantbot Technologies LP purchased a new stake in Loxo Oncology during the 3rd quarter valued at about $122,000. Ameritas Investment Partners Inc. boosted its holdings in Loxo Oncology by 31.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,758 shares of the biopharmaceutical company’s stock valued at $141,000 after acquiring an additional 419 shares during the period. Legal & General Group Plc boosted its holdings in Loxo Oncology by 8.4% during the 1st quarter. Legal & General Group Plc now owns 3,682 shares of the biopharmaceutical company’s stock valued at $154,000 after acquiring an additional 284 shares during the period. BNP Paribas Arbitrage SA boosted its holdings in Loxo Oncology by 4,388.0% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,244 shares of the biopharmaceutical company’s stock valued at $180,000 after acquiring an additional 2,194 shares during the period. Finally, Cambridge Investment Research Advisors Inc. purchased a new stake in Loxo Oncology during the 3rd quarter valued at about $212,000.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Stock Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related stocks with our FREE daily email newsletter.